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Abstract and keywords 
 
Hematopoietic stem cell transplantation (HSCT) associated immuncompromised state carries 
high risk of infectious complications. Mannose-binding lectin (MBL) is an acute phase 
protein involved in innate immune response. Serum MBL level is genetically determined and 
quite stable. According to literature, significant association was shown between low MBL 
concentrations and serious infections.  
The association between serum MBL level and frequency, severity of infections was studied 
in 186 patients following autologous HSCT.  
Double-monoclonal antibody sandwich ELISA was used to determine MBL antigen level in 
sera. MBL levels were measured around 100 days following transplantation, in a period 
without active infection.  
21 patients (11%) were MBL deficient. The median time of first infection and number of 
infections during the first posttransplant year were not significantly different between MBL 
deficients and non-MBL deficients. Occurrence and number of infections after HSCT 
correlated with MBL/CRP ratio. Number of severe infections was not higher among MBL 
deficients. Occurrence of infections after pre-engraftment period in first posttransplant year 
were significantly different in patient-groups separated by MBL cut-off level. 
MBL/CRP ratio might be a useful marker of infectious complications. MBL measurement 
may be helpful in antibiotic treatment, in case of MBL deficiency earlier and more intensive 
treatment may be indicated.  
 
mannose-binding lectin, autologous hematopoietic stem cell transplantation, infectious 
complication 
*Abstract
Highlights 
 Immuncompromised state carries high risk of infectious complications.  
 Time of first infection and number of infections during the first posttransplant year 
were not significantly different between MBL deficients and non-MBL deficients.  
 Occurrence and number of infections after HSCT correlated with MBL/CRP ratio. 
 Occurrence of infections after pre-engraftment period in first posttransplant year were 
significantly different in groups separated by MBL cut-off level. 
 MBL/CRP ratio might be a useful marker of infectious complications. 
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Introduction 1 
 2 
The innate immune system means immediate defence against infections and activates an 3 
adequate specific immune response [1]. When the adaptive immune response is immature or 4 
compromised, the innate immune system constitutes the principle defense against infection 5 
[2]. Mannose-binding lectin (MBL) is a C-type serum lectin that plays a central role in the 6 
innate immune response. MBL is produced by liver and is an acute phase protein [3,4]. The 7 
opsonic activity of MBL was first described in relation to immune deficiency in 1968 [5]. In 8 
plasma, MBL is associated with MBL-associated serine proteases (MASPs). MASP-2 is the 9 
enzyme of MBL/MASP complex needed for activation of complement factor C4 [6].  10 
The subunit of MBL consists of an N-terminal cross-linking region, a collagen-like domain, 11 
and a C-terminal carbohydrate-recognition domain (CRD) [7]. The oligomeric configuration 12 
permits to have multiple CRDs [8]. MBL binds microbial surface carbohydrates and mediates 13 
opsonophagocytosis directly and by activation of the lectin complement pathway [9,10]. 14 
Staphylococcus aureus and β-hemolytic group A streptococci bind MBL, but only a part of 15 
several species (E. coli, Klebsiella species, Haemophilus influenzae, etc.) showed significant 16 
binding [11]. MBL binding is inhibited by encapsulated organisms [10]. MBL allows 17 
opsonization of Aspergillus fumigatus, Candida albicans and Criptococcus neoformans, the 18 
main microorganisms involved in invasive fungal infections (IFI) [11,12].  19 
MBL is also involved in the recognition of self-targets, such as apoptotic and necrotic cells 20 
[13]. The endothelial cells exposed to oxidative stress bind MBL [14]. Neoplastic diseases are 21 
often associated with altered glycosylation patterns, so surfaces of malignant cells might be 22 
recognised by MBL as non-self [15]. 23 
The reason of low MBL level may be the actual MBL concentration or the level of functional 24 
activity. If the goal is to estimate the activity of MBL/MASP complex, so MBL pathway 25 
*Manuscript
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activity, anti-C4 antibody is needed to determine the amount of C4b bound to the surface 26 
[1,16]. The results of this assay correlate well with assay for MBL as antigen, except in case 27 
of MASP-2 deficiency [17,18].  28 
Serum MBL concentrations vary from 5 to 5000 ng/ml, because of genetic mutations within 29 
the gene and its promoters [19,20]. More than 10% of the general population may be 30 
classified as MBL deficient [1]. The majority of MBL-deficients are healthy without higher 31 
susceptibility for infections [21]. MBL deficiency may increase risk of infection when 32 
additional impairments of the immune system are present [22].  33 
There is a strong correlation between MBL concentration and genotype [23,24]. Individuals 34 
with the same genotypes may differ by 10-fold in MBL levels [25]. The capacity to increase 35 
MBL concentration during febrile neutropenia is associated with MBL2 genotype [26]. There 36 
is a small increase during acute phase responses [4]. This increase is slow (1-2 weeks after the 37 
inducing event) and modest (up to three-fold increase) [1].  38 
The variant monomers have less complement fixation capability and higher turnover [27]. The 39 
impairment of polymerization causes low serum levels of high molecular weight MBL and 40 
impaired MBL function [28].  41 
Gram-positive cocci are responsible for the majority of post-bone-marrow transplant 42 
bloodstream infections. The most common Gram-positive species are coagulase-negative 43 
Staphylococcus, Streptococcus viridans, MRSA, enterococci and Staphylococcus epidermidis 44 
[29,30]. Fluoroquinolones prophylaxis reduced the rate of Gram negative infections but it has 45 
a lower efficacy against Gram positive microorganisms [31]. The frequency of resistant Gram 46 
negative bacteraemia increases [32]. This may be associated with wider use of intravascular 47 
devices and fluoroquinolones prophylaxis [33]. Occurrence of PCP decreased due to the use 48 
of trimethoprim-sulphamethoxazole prophylaxis [34].  49 
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Viral infections present more frequently between day 31 and 100 post-transplant, the most 50 
important are CMV pneumonia and gastrointestinal involvement [35,36,37]. The most 51 
common early viral infection, HSV causes gingivostomatitis [38].  52 
The number of fungal infections increases post-HSCT and invasive infections can be a 53 
significant cause of morbidity and mortality. The two most common and clinically relevant 54 
pathogens are Candida and Aspergillus [39,40]. Fluconazole prophylaxis reduced the 55 
incidence of fungal infections [41,42]. IFI is one of the most life-threatening complications 56 
following treatment of hematologic malignancies, especially after allogeneic HSCT [43].  57 
The consequence of impaired MBL function would be an enlarged susceptibility to infections 58 
[24,44,45]. Low MBL concentration may be a risk factor for infection in patients receiving 59 
myelosuppressive chemotherapy [46,47,48]. Microbiologically proved systemic or 60 
disseminated infections are more common among patients with malignancy who have MBL 61 
deficiency and who received high-dose chemotherapy and autologous HSCT [49]. The 62 
duration and deepness of neutropenia influences the frequency and severity of infection [50]. 63 
MBL deficients experience longer episodes of febrile neutropenia [46]. Effector functions of 64 
MBL are severely compromised during neutropenia, because neutrophils are required for 65 
enhanced phagocytosis after MBL-induced complement activation [51].  66 
The normal MBL haplotype is associated with increasing MBL concentrations, whereas most 67 
patients with exon 1 mutations are not able to synthesize functional MBL and don’t have 68 
elevated serum MBL levels during acute phase response [26,46,52].  69 
According to some studies, that measured the incidence of fever as an end point, did not 70 
demonstrate an association with MBL deficiency. Febrile episodes and their duration did not 71 
vary on the basis of MBL levels [53,54,55]. Kilpatrick et al [55] found no relationship 72 
between MBL levels and chemotherapy-related infection. Rocha et al
 
[56] could not detect an 73 
association of mutations in MBL2 gene with the incidence of first infection. 74 
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MBL reactive carbohydrate epitopes occur on the surface of several cancer cell lines [15], 75 
there might be a general over-representation of MBL deficiency in patients with malignant 76 
hematological diseases [47].  77 
Oral mucositis is a common toxic side effect among patients receiving high-dose 78 
chemotherapy with autologous HSCT. Mucositis complicates treatment outcome by 79 
increasing the risk of infection, necessitating enteric or parenteral nutrition and prolonging 80 
hospitalization [57].  81 
 82 
Patients and methods 83 
 84 
The association between serum MBL level and frequency, severity and occurrence of 85 
infections has been studied in 186 patients following autologous HSCT. CRP was measured 86 
several times according to clinical decision, and the maximal CRP level during the first 14 87 
days after HSCT was taken in account. Correlation between infections and MBL/CRP ratio 88 
were determined. 89 
Subgroups, i.e. multiple myeloma (MM), non-Hodgkin (NHL) and Hodgkin lymphoma (HL) 90 
were formed and infectious complications have been compared. Among the examined 91 
patients, number of persons with NHL was 63 (female/male: 25/38, age: 52±11), 27 patients’ 92 
diagnosis was HL (female/male: 12/15, age: 34±9), and 94 patients had MM (female/male: 93 
55/39, age: 56±8). Two patients with other diagnosis were also involved in the trial. The 94 
control group consisted of 296 age- and gender-matched healthy individuals (female/male: 95 
156/140, age: 50±16 yrs) selected from consecutive blood donors. Control ones did not have 96 
any hematological or liver diseases. The control healthy group was the same as previously 97 
published in a large study from our Institute [58]. MBL serum levels and occurrence of MBL 98 
deficiency in case of healthy ones and patients with hematological diseases were compared.  99 
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Reaching the absolute neutrophil count (ANC) more than 1 G/L was taken in account as 100 
neutrophil engraftment and platelet count more than 20 G/L as platelet cell-line engraftment. 101 
We examined the distribution of microbiological results according to MBL level. It may be 102 
hypothesized that the progression, relapse following transplantation is related to MBL level 103 
and susceptibility to infections, among other parameters. 104 
The range of MBL level in healthy population varies between 5 and 5000 ng/ml, <100 ng/ml 105 
is defined as MBL deficiency. MBL antigen levels were measured around 100 days after 106 
transplantation, in a period without active infection. MBL level is genetically determined and 107 
quite stable. There is a small increase during acute phase responses [4].
 
In a few cases MBL 108 
concentration were also measured before and around 100 days after HSCT and were almost 109 
equal. Informed consent was signed by the examined patients. After blood samples were 110 
taken, native tubes were centrifuged for 15 minutes at 3000 RPM, then sera samples were 111 
stored at -70 °C in small aliquots until measuring. 112 
We used a double monoclonal antibody sandwich ELISA system adopted from Minchinton et 113 
al to determine MBL levels [23,58]. MBL assay was performed at the Clinical Research 114 
Centre of Debrecen University, without prior knowledge of the patients’ clinical information.  115 
Continuous variables were summarized as means and standard deviation or as medians and 116 
interquartile range and were compared with Mann-Whitney U-test or Student T-test. 117 
Kolmogorov-Smirnov and Chi-square tests were used to find out the distribution of variations. 118 
Kruskal-Wallis ANOVA by Ranks was used to compare data from more than two groups. 119 
Correlation of variables were analysed with Spearman Rank order correlation test. ROC curve 120 
analysis was performed to determine the cut-off level of MBL. P<0,05 was considered to be 121 
significant. Graphpad Prism 5 and MedCalc were used for statistical analysis.  122 
 123 
Results 124 
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 125 
Among the examined 186 patients with malignant hematological diseases, 21 patients were 126 
proved to be MBL deficient. 51 infectious episodes (elevated CRP level, fever, other clinical 127 
symptoms of infection) were found among MBL deficients, and 372 events were in MBL 128 
competent group during the first 360 days after HSCT. The median time of onset of first 129 
infection post-HSCT was day +7 [3;8] in MBL deficient and day +6 [4;8] among non-MBL 130 
deficient patients (Table 1). The distribution of MBL level and also MBL/CRP ratio were log-131 
normal among the patients, while distribution of CRP was normal with Kolmogorov-Smirnov 132 
and Chi-square tests (Figure 1). With Spearman Rank order correlation test, there were strong 133 
correlation between logarithmically transformed (log) MBL/CRP ratio and the time of onset 134 
of first infection (p=0,04, and after take in account the occurrence of infection as a censoring 135 
variation, p=0,0001) (Figure 2), and between log CRP and the time of first infection following 136 
transplantation (p<0,05). The time of first infection correlated neither with MBL level nor 137 
with log MBL (p=0,35). Correlation between log MBL and log CRP was almost significant 138 
(p=0,052), correlation between log MBL and log MBL/CRP ratio was significant (p=0,001) 139 
certainly. 140 
Occurrence of infections were similar among MBL deficient and MBL competent ones (2,429 141 
[1,478;3,379] vs 2,248 [1,993;2,516] infectious episodes/patient). Number of infections after 142 
HSCT correlated with CRP and MBL/CRP ratio but not with MBL level (Spearman Rank 143 
order correlation test, r=0,37, -0,17 and 0,07; p=0,02 and 0,34, respectively). Mann-Whitney 144 
U-test showed not significant relationship in case of MBL level and occurrence of first 145 
infection following transplantation (p=0,37), and MBL level and first infection in 14 days and 146 
100 days after HSCT. Connections of occurrence of infection in 14 and 100 days and before 147 
reaching ANC more than 1,5 G/L and log MBL were not significant with unpaired T-tests. 148 
7 
 
But relation of occurrence of first infection in 14 and 100 days and before neutrophil 149 
engraftment with log CRP and log MBL/CRP ratio were significant.  150 
Cut-off level of MBL according to occurrence of severe infections in posttransplant period, 151 
determined by ROC curve analysis was 823 ng/ml. Variables of the two patient-groups 152 
separated by MBL cut-off level were compared with Spearman Rank order correlation test. 153 
Number of infectious episodes (p=0.0611) and time of onset of first infection after HSCT 154 
(p=0.0905) were almost significantly different. Occurrence of infections after HSCT 155 
(p=0.0480) and occurrence of infections after the pre-engraftment period in first 156 
posttransplant year (during the period from day +14 until day 360) (p=0.0389) were 157 
significantly different in patient-groups separated by MBL cut-off level.  158 
Interestingly, MBL serum level was found to be significantly higher in the examined patients 159 
with hematological diseases compared to healthy control population (MBL median, 1479 160 
[380,8;2849] vs 1067 [253,5;2121], unpaired t-test, p= 0,005, significantly different). The 161 
occurrence of absolute MBL deficiency was not significantly different between hematology 162 
patients and healthy controls (11.4% vs 13.9%). The proportion of MBL deficients was the 163 
highest among HL patients (Table 2). MBL concentration of the control population and the 164 
examined patients according to diagnosis (NHL, HL, MM) were compared. Median MBL 165 
level was the highest among patients with NHL. The onset of first infection was the earliest 166 
among patients with HL (Table 3). The distribution of infectious episodes according to 167 
diagnosis is showed in Table 4.  168 
The most common infections after transplantation are respiratory tract infections and 169 
infections with high CRP, fever and severe mucositis.  170 
Time of neutrophil engraftment is related to MBL level significantly in MM group (Spearman 171 
Rank order correlation, p=0,024). Strong association was shown between platelet engraftment 172 
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time and MBL/CRP ratio among HL patients (p=0,003). Stem cell count and time to 173 
engraftment correlated well (p<0,001). 174 
Distribution of Gram positive and negative bacteria species in culture from the patients’ 175 
central venous catheter and blood is shown in Table 5 and 6. Positive results of central venous 176 
catheter culture (n=25) depend on log MBL and MBL/CRP ratio, but the relationship was not 177 
significant (t-test, p=0,23 and 0,15).  178 
We examined whether the progression, relapse following transplantation is related to the 179 
patients’ MBL levels or not. Association between occurrence of relapse and log MBL or log 180 
MBL/CRP were not significant (t-test, p=0,9 and 0,76). Among the examined patients, 23 181 
patients have relapsed during the first year following HSCT and other 45 patients later. Time 182 
to relapse was not related to MBL and MBL/CRP ratio.   183 
 184 
Discussion 185 
 186 
Initiation of complement system may occur via classical, alternative and lectin pathway [59]. 187 
MBL recognizes carbohydrate patterns [60]. Bacterial infections and autoimmune diseases are 188 
frequently associated with complement deficiencies [61]. MBL is a C-type serum lectin [62], 189 
the carbohydrate-binding sites allow interaction with the saccharide repeats on microbial 190 
surfaces but rarely associated with mammalian high-mannose structures [7]. MBL deficiency 191 
is a result of impaired assembly or stability of multimers [63]. MBL functions as a TLR co-192 
receptor that enables the molecule to coordinate and synchronize the innate immune system 193 
[64].  194 
The serum levels of functional MBL correlate with MBL2 coding genotypes [58]. MBL 195 
concentration is explained by polymorphisms in the promoter region and in exon 1 of the gene 196 
[65,66].  197 
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According to literature, MBL deficiency is associated with increased susceptibility to 198 
infectious diseases, mainly when adaptive immunity is compromised (in early childhood 199 
[45,48], or following chemotherapy [46,47,67]). A significant association was shown between 200 
low MBL concentrations and serious infections related to chemotherapy [47]. MBL deficients 201 
have a greater number of severe infections and experience their first severe infection earlier, 202 
compared to non-deficients [54]. The association between low MBL and infections was 203 
independent of whether patients received prophylactic antibiotics or GM-CSF or not [68]. 204 
The range of MBL level is between 5 and 5000 ng/ml, <100 ng/ml is defined as MBL 205 
deficiency. Serum MBL concentration is quite stable, shows small increase during acute 206 
phase responses [4]. Among the examined 186 patients 21 ones were MBL deficient. The 207 
time of onset of first infection post-HSCT was similar among MBL deficients and non-208 
deficients. There were strong correlation between log MBL/CRP ratio and time of first 209 
infection following HSCT, but the onset of first infection was not correlated significantly with 210 
log MBL. Occurrence of infections were similar among MBL deficient and MBL competent 211 
ones. The number of infections after HSCT correlated with MBL/CRP ratio but not with MBL 212 
level. Connections of occurrence of first infection in 14 and 100 days and before neutrophil 213 
engraftment and log MBL were not significant, but with log CRP and log MBL/CRP ratio 214 
were significant. We could not find strong association between MBL level and incidence, 215 
frequency and time of infections. An explanation can be that effector functions of MBL are 216 
severely compromised during neutropenia, because neutrophils are required for enhanced 217 
phagocytosis after MBL-induced complement activation [51]. Cut-off level of MBL 218 
according to occurrence of severe infections in posttransplant period, determined by ROC 219 
curve analysis was 823 ng/ml. Number of infections and time of first infection after HSCT 220 
were almost significantly different in groups separated by MBL cut-off level. Occurrence of 221 
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infections following HSCT and after the pre-engraftment period in first posttransplant year 222 
were significantly different in patient-groups separated by MBL cut-off level. 223 
MBL serum level was significantly higher in the examined patients compared to healthy 224 
control population. The proportion of MBL deficients was the highest and onset of first 225 
infection was the earliest among HL patients.  226 
Hematopoietic recovery and engraftment is related to patient-, disease-, and treatment-related 227 
variables [69]. Pre-engraftment phase is characterized by neutropenia, breaks in 228 
mucocutaneous barrier and vascular accesses required for patient care, and post-engraftment 229 
phase with impaired cell-mediated immunity [70].  230 
Stem cell count and time to engraftment correlated well in the patient-group. Time to 231 
neutrophil engraftment is related to MBL level significantly in MM group. Strong association 232 
was shown between platelet engraftment time and MBL/CRP ratio in HL patients.  233 
Infections might lead to delay or reduction in chemotherapy and might compromise the 234 
effectiveness of therapy [47]. Infections occur frequently and can be serious following high-235 
dose chemotherapy and HSCT. Infections might also compromise the engraftment of stem 236 
cells. MBL measurement may be helpful in antibiotic treatment, in case of MBL deficiency 237 
earlier and more intensive treatment may be indicated. The most common infections after 238 
transplantation are respiratory tract infections and infections with high CRP, fever and severe 239 
mucositis. The most of sepsis episodes are associated with infection of the CVC-entry-site 240 
[71]. Mostly Gram positive bacteria species were isolated in culture from the examined 241 
patients’ central venous catheter and blood. Positive results of central venous catheter culture 242 
depend on log MBL and MBL/CRP ratio, but not significantly. Infections are cured with 243 
appropriate antimicrobial therapy and in some cases with central venous catheter removal 244 
[33]. Among the examined patients, relapse and log MBL or log MBL/CRP were not 245 
associated significantly.  246 
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Extrahepatic transcription of MBL2 gene has been reported in small intestine [72,73]. 247 
Transcription of MBL2 is upregulated in inflamed intestinal tissue samples. MBL2 gene is 248 
expressed in immune cells infiltrating the inflamed gut [74]. MBL-deficients would be less 249 
able to prevent passage of bacteria from the gut to the circulation as compared to MBL 250 
competents58 [58]. Oral mucositis grade did not differ significantly between MBL deficient 251 
and MBL competent patients in our trial. 252 
MBL2 genotypes were not determined, as individuals with the same genotypes may differ by 253 
10-fold in MBL levels [25]. Measurement of MBL serum levels by ELISA allows reliable 254 
quantification of the functional activity of MBL pathway in vivo [75]. Procalcitonin levels 255 
were not determined, CRP level is used regularly to monitoring infectious complications in 256 
our institution. 257 
The relationship between increased susceptibility to infections and low MBL levels seen in 258 
some studies, seems less pronounced in patients with suppression of phagocytic activity due 259 
to intensive chemotherapy [1]. We could not find strong association between MBL level and 260 
incidence, frequency and time of infections. Log MBL/CRP ratio correlated well with time of 261 
first infection following HSCT. Lower MBL concentration may predispose to severe 262 
infections in immunocompromised state. Occurrence of infections after the pre-engraftment 263 
period in first posttransplant year were significantly different in patient-groups separated by 264 
MBL cut-off level. 265 
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  Total MBL <100 ng/ml MBL >100 ng/ml 
number of patients 186 21 165 
patients with infections 168 19 149 
infected/total (%) 90.3 90.5 90.3 
number of infectious 
episodes 423 51 372 
infectious episodes/ one 
patient 2.274 2.429 2.248 
development of first 
infection (day, median, 
range) 
6 [4;8] 7 [3;8] 6 [4;8] 
mean follow-up (day) 331 343 329 
    
bloodstream-infection 32 (7.6%) 3 (5.9%) 29 (7.8%) 
fever, high CRP, severe 
mucositis 106 (25.1%) 15 (29.4%) 91 (24.5%) 
upper respiratory tract 
infection 47 (11.1%) 6 (11.8%) 41 (11.0%) 
lower respiratory tract 
infection 63 (14.9%) 12 (23.5%) 51 (13.7%) 
oral mycosis 16 (3.8%) 1 (2.0%) 15 (4.0%) 
herpes zoster 14 (3.3%) 1 (2.0%) 13 (3.5%) 
HSV 7 (1.7%) 1 (2.0%) 6 (1.6%) 
EBV 1 (0.2%) 0 1 (0.2%) 
CMV 12 (2.8%) 1 (2.0%) 11 (3.0%) 
GI tract disease 56 (13.2%) 7 (13.7%) 49 (13.2%) 
elevated CRP level 42 (9.9%) 2 (3.9%) 40 (10.8%) 
urogenital and other 
infection 27 (6.4%) 2 (3.9%) 25 (6.7%) 
 
Table 1. The distribution of infections by MBL levels 
Table
  Control Patients NHL HL MM 
case number 296 184 63 27 94 
number of MBL-
deficients 41 21 7 5 9 
median MBL-
level (ng/ml) 
1067 
[253.5;2121] 
1479 
[380.8;2849]  
1623 
[406.2;2847] 
1365 
[322.3;2850] 
1338 
[324.6;2902] 
MBL deficient/ 
total (%) 13.9 11.4 11.1 18.5 9.6 
 
Table 2. MBL levels of the examined and healthy population 
Table
  Total NHL HL MM 
number of patients 184 63 27 94 
number of infectious 
episodes 415 186 67 162 
infections/one patient 2.27 2.95 2.48 1.72 
development of first 
infection (day, median, 
range) 
6 [3;8] 4 [2.5;6] 4 [0;7] 8 [6;9] 
grade of mucositis 
(mean) 1.44 1.56 1.5 1.34 
MBL level (ng/ml) 
(median, range) 
1479 
[380.8;2849]  
1623 
[406.2;2847] 
1365 
[322.3;2850] 
1338 
[324.6;2902] 
mean follow-up (day) 327 330 324 325 
 
Table 3. Comparison of MBL levels and infections according to diagnosis 
Table
  Total NHL HL MM 
number of infectious 
episodes 415 (100%) 186 (100%) 67 (100%) 162 (100%) 
bloodstream-infection 30 (7.2%) 10 (5.4%) 7 (10.4%) 13 (8.0%) 
fever, high CRP, severe 
mucositis 95 (22.9%) 47 (25.3%) 16 (23.9%) 32 (19.8%) 
upper respiratory tract 
infection 46 (11.1%) 18 (9.7%) 6 (9.0%) 22 (13.6%) 
lower respiratory tract 
infection 62 (14.9%) 26 (14.0%) 12 (17.9%) 24 (14.8%) 
oral mycosis 16 (3.9%) 7 (3.8%) 1 (1.5%) 8 (4.9%) 
herpes zoster 13 (3.1%) 5 (2.7%) 3 (4.5%) 5 (3.1%) 
HSV, EBV, CMV 20 (4.8%) 10 (5.4%) 1 (1.5%) 9 (5.6%) 
GI tract disease 56 (13.5%) 30 (16.1%) 7 (10.4%) 19 (11.7%) 
elevated CRP level 51 (12.3%) 21 (11.3%) 10 (14.9%) 20 (12.3%) 
urinary tract and other 
infection 26 (6.3%) 12 (6.5%) 4 (6%) 10 (6.2%) 
 
Table 4. The distribution of infections by diagnosis 
Table
culture of central vein 
catheter 
Total MBL <100 MBL >100 
number of patients 100 17 83 
positive result of culture 25 (100%) 7 (100%) 18 (100%) 
Staphylococcus 
epidermidis 
10 (40%) 3 (42.9%) 7 (38.9%) 
Staphylococcus 
coagulase negative 
3 (12%) 1 (14.3%) 2 (11.1%) 
Staphylococcus aureus 1 (4%) 0 1 (5.6%) 
Enterococcus faecalis 5 (20%) 1 (14.3%) 4 (22.2%) 
Streptococcus alpha-
hemolising  
1 (4%) 1 (14.3%) 0 
Klebsiella pneumoniae 1 (4%) 1 (14.3%) 0 
Pseudomonas 
aeruginosa 
1 (4%) 0 1 (5.6%) 
Acinetobacter 
baumannii 
2 (8%) 0 2 (11.1%) 
Bacillus 1 (4%) 0 1 (5.6%) 
 
Table 5. Results of culture from central venous catheter 
Table
Blood culture Total MBL<100 MBL>100 
number of patients 186 21 165 
positive result of culture 
55 (100%)  
(43 patient) 
5 (100%)  
(4 patient) 
50 (100%)  
(39 patient) 
Staphylococcus 
epidermidis 
17 (30.9%) 1 (20%) 16 (32%) 
Staphylococcus hominis 5 (9.1%) 2 (40%) 3 (6%) 
Staphylococcus 
hemolyticus 
6 (10.9%) 1 (20%) 5 (10%) 
Staphylococcus 
coagulase negative 
9 (16.4%) 0 9 (18%) 
Staphylococcus aureus 2 (3.6%) 0 2 (4%) 
Enterococcus faecalis 4 (7.3%) 1 (20%) 3 (6%) 
Streptococcus 3 (5.5%) 0 3 (6%) 
Propionibacterium 
acnes 
5 (9.1%) 0 5 (10%) 
Pseudomonas 
aeruginosa 
3 (5.5%) 0 3 (6%) 
other Gram negative  1 (1.8%) 0 1 (2%) 
 
Table 6. Results of blood culture according to MBL level 
Table
 Variable: MBL, Distribution: Log-normal
Kolmogorov-Smirnov d = 0.14984, p < 0.01
Chi-Square test = 61.29336, df = 8 (adjusted) , p = 0.00000
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Figure 1. The distribution of MBL level in the examined patient group with hematological 
malignancies 
 
Figure
 
 
Figure 2. Correlation between log MBL/CRP and log time of first infection 
Figure
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